目的 分析喹硫平联合丁螺环酮治疗精神分裂症(SCH)患者的效果.方法 选取2020年4月至2023年3月本院收治的100例SCH患者,按照奇偶顺序分为观察组与对照组.对照组采用喹硫平治疗,观察组采用喹硫平联合丁螺环酮治疗.比较两组患者症状评分、血清指标水平及生活质量.结果 治疗后,观察组PANSS评分低于对照组(P＜0.05).治疗后,观察组胶质源性神经营养因子(GDNF)、脑源性神经营养因子(BDNF)、5-羟色胺(5-HT)水平高于对照组(P＜0.05).治疗后,观察组GQOLI-74评分高于对照组(P＜0.05).结论 喹喹硫平联合丁螺环酮治疗SCH可减轻患者的临床症状,调节神经递质水平,改善其生活质量.
Objective To analyze the effect of quetiapine combined with buspirone in the treatment of patients with schizophrenia(SCH).Methods 100 SCH patients admitted to our hospital from April 2020 to March 2023 were selected and divided into observation group and control group according to odd even order.The control group was treated with quetiapine,while the observation group was treated with quetiapine combined with buspirone.The symptom score,serum indicator levels and quality of life were compared between the two groups.Results After treatment,the PANSS score of the observation group was lower than that of the control group(P＜0.05).After treatment,the glial-derived neurotrophic factor(GDNF),brain derived neurotrophic factor(BDNF)and 5-hydroxytryptamine(5-HT)levels of the observation group were higher than those of the control group(P＜0.05).After treatment,the GQOLI-74 score of the observation group was higher than that of the control group(P＜0.05).Conclusions Quetiapine combined with buspirone can relieve the clinical symptoms,regulate the neurotransmitter levels,and improve the quality of life of SCH patients.
胡广旭;赵云东;孙连风
驻马店市精神病院精神五科,河南省驻马店 463002
临床医学
喹硫平;丁螺环酮;精神分裂症
Quetiapine;Buspirone;Schizophrenia
《临床医学工程》 2024 (005)
539-540 / 2
河南省医学科技攻关计划联合共建项目(LHGJ20200528)
10.3969/j.issn.1674-4659.2024.05.0539
评论